ArticleBMC gastroenterology2025
Differences and clinical significance of liver - kidney function parameters, inflammatory markers and peripheral blood T lymphocyte subsets in patients with HBV - related acute - on - chronic liver failure.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quantitative Characterization of the Serum Elemental Signatures in HBV Infection.Biological trace element research · 2026Article
- Association of NPAR with 90-day mortality in predominantly acute-on-chronic liver failure.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe study aimed to explore the changes and clinical significance of hepatic-renal functions, inflammatory markers, and peripheral blood T lymphocyte subsets in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF).
methods80 HBV treated in First Hospital of Shanxi Medical University from November 2020 to May 2023 were selected as the objects of study, and divided into observation group (n = 40) and control group (n = 40) based on whether ACLF occurred. The liver and kidney function parameters, inflammatory factors, and peripheral blood T lymphocyte subsets (CD3 + and CD4 + T-cell percentages) were detected in both groups, and the associations of HBV-DNA load with the changes in the liver cirrhosis index hyaluronic acid (HA), AST, BUN, high-sensitivity C-reactive protein (hs-CRP), and peripheral blood T lymphocyte index cluster of CD3
resultsHBV-DNA load was significantly higher in the observation group than in the control group, HA and procollagen type III (PCIII) levels were higher, as were ALT, AST, TBIL, BUN, Cr, hs-CRP, and TNF-α levels, and the CD4 + and CD3 + percentages were lower in the observation group than in the control group. The amount of HBV-DNA was positively connected with the changes in HA, AST, BUN and hs-CRP, but negatively associated with the changes in CD3
conclusionThe risk of ACLF becomes higher in hepatitis B patients with the increase in HBV-DNA load and the inflammatory reaction of the body, and the decline in immune function of T lymphocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.